Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling

BACKGROUND: We previously showed that activation of the nuclear factor of activated T cells (NFAT)1/Fas ligand (FasL) pathway induces glioma cell death. Lithium (Li) is an inhibitor of glycogen synthase kinase (GSK)-3 that activates NFAT1/FasL signalling. Temozolomide (TMZ) inhibits GSK-3 and activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sheng, Meng, Lingxuan, Jiang, Yang, Cheng, Wen, Tie, Xinxin, Xia, Junzhe, Wu, Anhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482734/
https://www.ncbi.nlm.nih.gov/pubmed/28359080
http://dx.doi.org/10.1038/bjc.2017.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482734/
https://www.ncbi.nlm.nih.gov/pubmed/28359080
http://dx.doi.org/10.1038/bjc.2017.89

Ejemplares similares